Nektar Therapeutics
NKTR36.810USD
+1.690+4.81%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
723.41MValor de mercado
PerdaP/L TTM
Mais detalhes de Nektar Therapeutics Empresa
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Informações de Nektar Therapeutics
Código da empresaNKTR
Nome da EmpresaNektar Therapeutics
Data de listagemMay 03, 1994
CEORobin (Howard W)
Número de funcionários61
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 03
Endereço455 Mission Bay Boulevard South
CidadeSAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94158
Telefone18554826587
Sitehttps://www.nektar.com/
Código da empresaNKTR
Data de listagemMay 03, 1994
CEORobin (Howard W)
Executivos da empresa Nektar Therapeutics
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
68.40K
+21667.00%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
19.04K
-3867.00%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Corey Davis
Mr. Corey Davis
Managing Director
Managing Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
68.40K
+21667.00%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
19.04K
-3867.00%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
Rest of world
97.05M
98.60%
United States
1.38M
1.40%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 7 de fev
Atualizado em: sáb, 7 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BVF Partners L.P.
6.28%
The Vanguard Group, Inc.
5.03%
Susquehanna International Group, LLP
4.55%
Morgan Stanley & Co. LLC
4.34%
Farallon Capital Management, L.L.C.
3.89%
Outro
75.92%
Investidores
Investidores
Proporção
BVF Partners L.P.
6.28%
The Vanguard Group, Inc.
5.03%
Susquehanna International Group, LLP
4.55%
Morgan Stanley & Co. LLC
4.34%
Farallon Capital Management, L.L.C.
3.89%
Outro
75.92%
Tipos de investidores
Investidores
Proporção
Hedge Fund
31.98%
Investment Advisor
23.75%
Investment Advisor/Hedge Fund
8.82%
Research Firm
7.03%
Individual Investor
0.82%
Pension Fund
0.76%
Venture Capital
0.75%
Sovereign Wealth Fund
0.25%
Outro
25.84%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
373
14.85M
73.02%
+2.42M
2025Q3
342
9.79M
51.46%
-2.29M
2025Q2
342
8.92M
53.56%
-2.95M
2025Q1
408
8.48M
68.15%
-4.47M
2024Q4
427
136.20M
73.84%
-69.28M
2024Q3
442
143.71M
78.07%
-57.20M
2024Q2
458
138.43M
75.38%
-54.08M
2024Q1
477
115.32M
62.79%
-91.21M
2023Q4
499
122.94M
64.45%
-94.24M
2023Q3
522
148.15M
77.94%
-68.45M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BVF Partners L.P.
1.28M
6.28%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
948.65K
4.66%
+219.16K
+30.04%
Sep 30, 2025
Susquehanna International Group, LLP
924.90K
4.55%
+703.00K
+316.82%
Sep 30, 2025
Morgan Stanley & Co. LLC
883.58K
4.34%
+822.95K
+1357.26%
Sep 30, 2025
Farallon Capital Management, L.L.C.
791.00K
3.89%
+791.00K
--
Sep 30, 2025
Two Sigma Investments, LP
613.14K
3.01%
+533.75K
+672.27%
Sep 30, 2025
Emerald Advisers LLC
556.45K
2.74%
+382.56K
+220.00%
Sep 30, 2025
Millennium Management LLC
545.99K
2.68%
-103.04K
-15.88%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
476.31K
2.34%
+178.50K
+59.94%
Sep 30, 2025
Nantahala Capital Management, LLC
418.52K
2.06%
-291.24K
-41.03%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco Dorsey Wright Healthcare Momentum ETF
4.55%
Simplify Health Care ETF
3.22%
Simplify Propel Opportunities ETF
2.69%
State Street SPDR S&P Pharmaceuticals ETF
1.72%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.48%
Invesco NASDAQ Future Gen 200 ETF
1.17%
Invesco Dorsey Wright SmallCap Momentum ETF
0.95%
iShares U.S. Pharmaceuticals ETF
0.46%
Invesco RAFI US 1500 Small-Mid ETF
0.13%
Schwab U.S. Small-Cap ETF
0.03%
Ver Mais
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção4.55%
Simplify Health Care ETF
Proporção3.22%
Simplify Propel Opportunities ETF
Proporção2.69%
State Street SPDR S&P Pharmaceuticals ETF
Proporção1.72%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.48%
Invesco NASDAQ Future Gen 200 ETF
Proporção1.17%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção0.95%
iShares U.S. Pharmaceuticals ETF
Proporção0.46%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.13%
Schwab U.S. Small-Cap ETF
Proporção0.03%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Jun 04, 2025
Merger
15→1
Data
Data ex-dividendo
Tipo
Proporção
Jun 04, 2025
Merger
15→1
